New drug duo takes on tough liver cancers

NCT ID NCT06789848

Recruiting now Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial is testing whether a combination of two immune-boosting drugs, ligufalimab and cadonilimab, can shrink advanced liver or bile duct cancers that have stopped responding to prior treatments. About 64 adults will receive the drugs by IV every three weeks. The main goal is to see how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ligufalimab and Cadonilimab (two immune-boosting drugs given by IV)
What this could lead to: If it works, this could offer a new treatment option for people with advanced liver or bile duct cancers that have not responded to other therapies.
What could go wrong: This is an early phase 2 trial with only 64 participants, so results may not apply to everyone. The drugs can cause immune-related side effects, and the cancer may still grow.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HEPATOCELLULAR CARCINOMA BILIARY TRACT CANCER REFRACTORY HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.